Editas Medicine (EDIT) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, t ...

Shares of Editas Medicine (EDIT) plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its lead gene editing therapy, reni-cel, which is being developed for certain non-malignant hematologic diseases, or potentially out-license rights to the treatment entirely, amid a significant cash crunch. Editas firmly believes that this decision is in the best interests of its patients and shareholders, as a potential partnership agreement would allow for further development and ultim ...

Editas Medicine, Inc. (EDIT) announced that it has entered into a collaboration and nonexclusive license agreement with Canada-based privately held company Genevant Sciences to develop in vivo gene editing medicines. Shares of Editas were up 2.4% in after-hours trading on Oct. 21, following the announcement of the news. The partnership aims to leverage Editas' CRISPR Cas12a genome editing systems with Genevant's proprietary lipid nanoparticle (LNP) technology to develop novel mRNA-LNP gene editing therapies ...

Company Overview - Editas Medicine, Inc. held a Strategic Update Conference Call on October 22, 2024, at 8:00 AM ET, featuring key executives including the CEO, CFO, and Chief Scientific Officer [1]. Participants - The conference call included participation from various financial institutions such as Citi, Barclays, Baird, Wells Fargo, and JPMorgan Chase, among others [1]. Future Expectations - The company made forward-looking statements regarding its future expectations, plans, and prospects, which are protected under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 [2].

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio, today announced that they have entered into a collaboration and nonexclusive license agreement to combine Editas Medicine’s CRISPR Cas12a genome editing systems with Genevant’s propr ...

CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar on Tuesday, October 22, 2024, at 8:00 a.m. ET to share achievement of in vivo preclinical proof of concept data and business development and financial updates. Webinar Presentation Details: The live and archived webcast of the Company's webinar presentation will be accessible through this webcast link, or through the Ev ...

Shares of Editas Medicine, Inc. (EDIT, Financial), a biopharmaceutical company, experienced a notable drop of 5.18%. The stock is currently priced at $3.21 per share, with a trading volume of 976,255 shares and a turnover rate of 1.18%. The price fluctuation stands at 6.36%. According to recent financial reports, Editas Medicine generated $513,000 in revenue but reported a net loss of $67.61 million. The earnings per share stood at -$0.82, and the gross profit was -$907,000, resulting in a priceto-earnings ...

Editas Medicine, Inc. (NASDAQ:EDIT) Chardan's 8th Annual Genetic Medicines Conference October 1, 2024 3:45 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - VP Corporate Communications and IR Conference Call Participants Geulah Livshits - Chardan Geulah Livshits I'm Geulah Livshits, a biotech analyst at Chardan and it's my pleasure to introduce Erick Lucera, our CFO; and Cristi Barnett, VP Corporate Communications and IR at Editas. Thank you both for joining us today. Question-and-Answer Sessio ...

Editas Medicine, Inc. (NASDAQ:EDIT) Chardan's 8th Annual Genetic Medicines Conference October 1, 2024 3:45 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - VP Corporate Communications and IR Conference Call Participants Geulah Livshits - Chardan Geulah Livshits I'm Geulah Livshits, a biotech analyst at Chardan and it’s my pleasure to introduce Erick Lucera, our CFO; and Cristi Barnett, VP Corporate Communications and IR at Editas. Thank you both for joining us today. Question-and-Answer Sessio ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial. It has been about eight months since my previous Editas Medicine (NASDAQ: EDIT ) article , where I discussed the company's efforts to focus on their three key pillars of advancing reni-cel, progressing their invivo editing pipeline, and expanding busine ...